New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
08:16 EDTAGN, AERIAerie Pharmaceuticals won't be hurt by Allergan move, says RBC Capital
After Allergan (AGN) said it plans to initiate a Phase III trial for its long-acting prostaglandin glaucoma treatment, RBC Capital does not expect Allergan's move to hurt Aerie (AERI), as Aerie's Roclatan has demonstrated statistically significant superiority to a prostaglandin, according to the firm. Moreover, RBC believes that the glaucoma market is large enough to enable multiple products to succeed. It recommends buying Aerie's stock at current levels.
News For AERI;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 6, 2015
08:22 EDTAGNAllergan to host special shareholder meeting
Subscribe for More Information
March 2, 2015
16:08 EDTAERIAerie Pharmaceuticals reports Q4 EPS (69c), consensus (46c)
Subscribe for More Information
February 27, 2015
08:34 EDTAGNAllergan says FDA approves Natrelle Inspira breast implants
Subscribe for More Information
February 24, 2015
07:31 EDTAERIRBC Capital to hold a conference
Subscribe for More Information
February 20, 2015
07:08 EDTAGNAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use